ISHL12 2022 | Recent clinical developments in the treatment landscape for older patients with HL
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, comments on how the treatment landscape for older patients with Hodgkin lymphoma (HL) is changing with the introduction of novel agents. Dr Bröckelmann first explains the need to better understand the biological distinctions between younger and older patients, and then highlights the efficacy of brentuximab vedotin, as well as challenges associated with the use of anti-PD1-based treatment in this patient population. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Research funding: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Advisory boards: Takeda
Speakers’ bureau: BeiGene, MSD
